EXCLUSIVE: Milestone Scientific Announces Medicare Price Assignment For CompuFlo Epidural System For Back Pain Covering Additional US States
EXCLUSIVE: Milestone Scientific Announces Medicare Price Assignment For CompuFlo Epidural System For Back Pain Covering Additional US States
On Tuesday, Milestone Scientific Inc (NYSE:MLSS) announced that Novitas Solutions, Inc., a Jurisdictional Medicare Administrative Contractor (JMAC), has granted a Medicare Part B Physician payment rate for the company's CompuFlo Epidural System under the American Medical Association's (AMA) technology-specific Category III CPT code CPT0777T (real-time pressure-sensing epidural guidance system when used in conjunction with a primary ESI procedure).
週二，Milestone Scientific Inc. (NYSE:MLSS)宣佈，醫療保險權利判定機構（JMAC）Novitas Solutions，Inc.已經根據美國醫學協會(AMA)的技術特定代碼 第III CPT代碼CPT777萬億（即實時壓力感應硬膜外導航系統與初級ESI程序相結合使用時的硬膜外導航系統）爲該公司的CompuFlo Epidural系統授予了醫療保險(b)醫生支付比率。
This new price assignment applies to two Medicare regions:
這個新的價格分配適用於兩個醫療保險區域：
- Jurisdiction L (JL) includes Delaware, District of Columbia, Maryland, New Jersey, and Pennsylvania.
- Jurisdiction H (JH) includes Arkansas, Colorado, Louisiana, Mississippi, New Mexico, Oklahoma, and Texas.
- L大單（JL）包括特拉華州，哥倫比亞特區，馬里蘭州，新澤西州和賓夕法尼亞州。
- H大單（JH）包括阿肯色州，科羅拉多州，路易斯安那州，密西西比州，新墨西哥州，俄克拉荷馬州和德克薩斯州。
The pricing assignment by Novitas represents a significant step forward in Milestone Scientific's strategy to ensure broad coverage and appropriate payment for the CompuFlo technology when deemed medically necessary and clinically appropriate for Medicare beneficiaries.
Novitas的價格分配代表了Milestone Scientific確保CompuFlo技術在對醫保受益人進行醫療必要性和臨床適當性評估時獲得廣泛覆蓋和適當支付的重要一步。
This decision follows the recently announced Medicare Jurisdiction N (JN) pricing assignment in Florida by First Coast Service Options Inc.
此決定是繼First Coast Service Options Inc.最近宣佈向佛羅里達醫療保險區域N（JN）的醫療保險價格分配之後做出的。
Also Read: EXCLUSIVE: Milestone Scientific Announces Favorable Medicare Pricing For CompuFlo Epidural System For Back Pain Covering Florida.
閱讀更多: Milestone Scientific宣佈CompuFlo脊柱後路硬膜外導航系統獲得佳美醫療價格優惠。
An estimated 3.0 million epidural steroid injection (ESI) procedures are performed yearly in these three jurisdictions (JL, JH, JN), representing approximately one-third of the total ESI procedures for treating chronic back pain in the United States.
每年在這三個醫療保險區域（JL，JH，JN）中進行約300萬次硬膜外腎上腺皮質類固醇注射（ESI）程序，對治療慢性背痛的總ESI程序數量的約三分之一。
Additionally, Medicare is expected to account for up to 40% of the clinical practice volume, representing an initial addressable market of approximately $250 million among Medicare patients in these three jurisdictions, the company said.
此外，該公司表示，醫療保險預計將佔據最多40%的臨床實踐成交量，這代表了這三個醫療保險區域內約25000萬美元的初始可尋址市場。
The CompuFlo Epidural System uses Milestone Scientific's patented Dynamic Pressure Sensing technology, which provides real-time feedback to ensure accurate needle placement during epidural procedures. This technology is designed to reduce the morbidity, pain, and discomfort associated with traditional epidural techniques.
CompuFlo Epidural System採用Milestone Scientific的專利動態壓力傳感技術，可以提供實時反饋，以確保硬膜外程序導管的準確放置。這種技術旨在減少傳統硬膜外技術所帶來的發病率、疼痛和不適。
Price Action: MLSS stock is trading lower by 4.49% at $0.83 premarket at the last check on Tuesday.
股價行動：截至週二最後交易時段，MLSS股價預市下跌4.49%，報0.83美元。
- AnaptysBio Investigational Arthritis Drug Might Have Better Efficacy Profile Than Eli Lilly's: Analyst.
- AnaptysBio調查用藥可能比Eli Lilly的更具有效性:分析師。